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Abstract
Introduction: The effect of certolizumab pegol (CZP) on patient-reported outcomes (PROs) was investigated in
1063 patients with rheumatoid arthritis (RA) from the REALISTIC trial (double-blind, placebo-controlled to week 12,
open-label to week 28; randomized 4:1 [CZP:placebo]). Correlations between PROs and RA signs and symptoms,
and the relative efficacy of these measures, were examined.
Methods: Adults with RA and an inadequate response to at least one disease-modifying antirheumatic drug were
enrolled. PROs assessed included physical function (using the Health Assessment Questionnaire-Disability Index),
pain, fatigue, sleep disturbance, Patient Global Assessment of Disease Activity (PtGA), Routine Assessment of Patient
Index Data 3 (RAPID3), and Rheumatoid Arthritis Disease Activity Index (RADAI).
Results: Early significant and clinically meaningful improvements in all PROs were observed to week 12 with CZP
vs. placebo and were maintained to the end of the trial (week 28). At week 12, up to one-third more CZP patients
showed improvements compared with placebo that were greater than or equal to the minimal clinically important
difference (MCID) in fatigue, sleep problems, pain, PtGA, RADAI, and RAPID3. The changes in PROs were correlated
with clinical measures of disease activity, including the Disease Activity Score in 28 joints using C-reactive protein as
well as tender and swollen joint counts.
Conclusions: Rapid improvements in PROs were seen in patients with RA treated with CZP. The magnitude of
improvement exceeded the MCID in multiple domains and demonstrated that CZP improves aspects of health-
related quality of life that are meaningful to patients and superior to placebo. PROs provide information
complementary to clinical outcomes in assessment of treatment benefits.
Trial registration: ClinicalTrials.gov identifier: NCT00717236. Registered on 15 July 2008.
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Introduction
Patient-reported outcomes (PROs), such as physical func-
tion, pain, and fatigue, reflect the important effects of
rheumatoid arthritis (RA) on the daily lives of people living
with the disease. Several studies have suggested that PROs
discriminate between treatment effects and physician-
reported clinical outcomes [1–3]. By using both, a physician
should have a more comprehensive assessment of a pa-
tient’s status. Assessment of PROs in clinical trials is now
recommended by the U.S. Food and Drug Administration
[4] and the European Medicines Agency [5] for the evalu-
ation of medications for chronic diseases such as RA. There
is interest in how PROs compare to each other, their sensi-
tivity to change, and how they differentiate between treat-
ments in blinded, randomized clinical trials (RCTs).
Self-reported disease activity questionnaires, such as the
Rheumatoid Arthritis Disease Activity Index (RADAI) and
the Routine Assessment of Patient Index Data 3 (RAPID3),
offer a patient-focused approach to the clinical manage-
ment of RA [6–8]. RAPID3 is an index of three PRO mea-
sures in the American College of Rheumatology (ACR)
Core Data Set [9] (physical function, pain, and Patient
Global Assessment of Disease Activity [PtGA]), but it does
not include formal joint counts. RADAI includes a patient
self-assessment of joint tenderness and pain in 16 joint
areas, current and past global disease activity, and morning
stiffness [6, 7]. Neither index employs a physician joint
count or determination of an acute-phase reactant.
Most clinical trials have strict inclusion and exclusion cri-
teria, excluding patients with many of the comorbidities
commonly seen in clinical practice and enrolling a more
homogeneous and less complicated population than that
usually encountered in clinical practice settings. Evaluations
of anti–tumor necrosis factor (anti-TNF) therapy in groups
more representative of the clinical setting are lacking. The
REALISTIC (RA EvALuation In Subjects receiving TNF
Inhibitor Certolizumab pegol) study, which was double-
blinded and placebo-controlled to week 12 (randomizing
patients in a 4:1 fashion [certolizumab pegol:placebo]) and
open-label thereafter, had fewer exclusion criteria than
most clinical trials. This study demonstrated that the PEGy-
lated Fc-free anti-TNF agent certolizumab pegol (CZP), ei-
ther as monotherapy or in addition to current treatment, is
efficacious on the basis of clinical response criteria in a
broad group of patients with active, inadequately controlled
RA [10].
In this article, we investigate the efficacy of CZP in pa-
tients with RA with regard to PROs of physical function,
pain, fatigue, sleep, and PtGA in the REALISTIC study and
examine the correlations between PROs and clinical indices
of RA signs and symptoms, including the Disease Activity
Score in 28 joints using C-reactive protein (DAS28[CRP])
and formal joint counts. Finally, the relative efficacy of
composite PROs (RADAI and RAPID3) and clinical indices
of RA signs and symptoms are compared to ascertain their
respective sensitivity to therapeutic efficacy in the CZP-
treated population.
Material and methods
Patients and study design
Detailed methods of the REALISTIC study have been
published previously [10]. Briefly, the trial enrolled 1063
patients aged ≥18 years with adult-onset RA, as defined by
the 1987 ACR criteria [11], of ≥3 months’ duration, with
an unsatisfactory response to or intolerance of at least one
disease-modifying antirheumatic drug (DMARD; metho-
trexate [MTX], leflunomide, sulfasalazine, chloroquine or
hydroxychloroquine, azathioprine, and gold). Patients
were stratified by baseline MTX use, prior anti-TNF use,
and disease duration (<2 years vs. ≥2 years) and random-
ized 4:1 to receive, in addition to their existing treatment,
either (1) a CZP 400-mg loading dose at weeks 0, 2, and 4,
followed by CZP 200 mg every 2 weeks; or (2) placebo in-
jection (control) every 2 weeks for the initial 12-week
double-blind RCT. After completing the 12-week RCT,
patients could enter the open-label phase and receive CZP
200 mg every 2 weeks (following the loading dose for pa-
tients originally randomized to placebo). The trial was car-
ried out in compliance with the principles of the
Declaration of Helsinki and was approved by the institu-
tional review boards at each participating center. The full
details of all institutional review boards are provided at
the end of the main text in the Acknowledgments section.
All patients provided written informed consent.
Efficacy evaluations
PROs were secondary and exploratory endpoints in the
REALISTIC study. They included assessments of physical
function (Health Assessment Questionnaire-Disability Index
[HAQ-DI]), arthritis pain, and PtGA. Pain and PtGA were
both scored on 100-mm visual analogue scales (VASs)
[12]. PtGA was scored from 0 (“very good, no symptoms”)
to 100 (“very poor, severe symptoms”), and pain was
scored from 0 (“no pain”) to 100 (“most severe pain”). The
minimal clinically important difference (MCID) for both
has been established as a 10-mm decrease (i.e., improve-
ment) from baseline [13, 14]. The MCID for the HAQ-DI
was prespecified as a 0.22-point improvement (i.e., −0.22
change), based on previous trials [15, 16].
RAPID3 is an index composed of three routine PROs
assessed on a standard patient questionnaire [7]: the
HAQ-DI, the pain VAS, and the PtGAVAS. It was investi-
gated as a post-hoc analysis. To calculate the RAPID3
score, the raw 0–3 score for physical function in the
HAQ-DI is multiplied by 3.33 and the pain and PtGAVAS
scores are each divided by 10, to give scores of 0–10. The
HAQ-DI, pain, and PtGA scores are then summed for a
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raw score of 0–30. The MCID for RAPID3 is a 3.6-point
decrease from baseline [17].
Exploratory endpoints included assessments of fatigue
according to the 10-point Fatigue Assessment Scale
(FAS) [14], sleep quality and quantity as measured by
the Sleep Problem Index II domain of the 12-item Med-
ical Outcomes Study Sleep Scale (MOS-SPI) [18], and
disease activity from the patient’s perspective as assessed
with the RADAI [6].
Fatigue was scored from 0 (“no fatigue”) to 10 (“fatigue
as bad as you can imagine”), with MCID defined as a 1-
point decrease from baseline [14]. Sleep over the last
4 weeks was assessed using 12 questions relating to the
time taken to fall asleep, quality of sleep, amount of
waking during the night, and the effect of sleep on day-
time functioning. The MCID reported for MOS-SPI is a
decrease ≥6 [14].
The RADAI is a self-administered, 5-item question-
naire [6] used to assess the following: (1) global disease
activity in the past 6 months, (2) disease activity in terms
of tender and swollen joints, (3) arthritis pain, (4) dur-
ation of morning stiffness, and (5) tender joints (16-joint
count). To calculate the RADAI joint score (RADAI-JS),
each joint in the assessment of tender joints (item 5
above, 16-joint count) is scored from 0 to 3, and subse-
quently these scores are summed (maximal sum score
48) and multiplied by 10/48 to adjust the overall score
to a range of 0–10. To calculate the RADAI total score
(RADAI-TS), the five items are combined into a single
index of patient-assessed disease activity with a range of
0–10. The MCID for the RADAI-TS is a 1-point de-
crease from baseline [19].
All PROs except MOS-SPI were assessed at weeks 0,
2, 6, 12, 20, and 28 and at completion of or withdrawal
from the trial. MOS-SPI was assessed at all time points
except week 2. We report the PRO findings for the 12-
week, double-blind phase of the REALISTIC study and
for the subsequent open-label phase through week 28.
Statistical analysis
PRO analyses were carried out using the intention-to-
treat (ITT) population, which included all randomized
patients. The results are reported as ITT unless other-
wise specified.
Least squares mean change from baseline (CFB) in
HAQ-DI, pain, fatigue, sleep problems, PtGA, RAPID3,
and RADAI-TS were obtained using analysis of covari-
ance (ANCOVA) with factors for treatment, baseline
MTX status, prior anti-TNF use, disease duration cat-
egory (<2 years vs. ≥2 years), and baseline response as
covariates. Missing data were accounted for by using the
last observation carried forward. All reported p values
and confidence intervals are nominal and can be inter-
preted only in an exploratory manner. p values were
reported for odds ratios rather than for direct compari-
son between percentages of patients with improvements
greater than or equal to the MCID.
Post hoc comparisons of the proportion of patients
reporting improvements greater than or equal to the
MCID for RADAI, RAPID3, and other PROs were per-
formed. For exploratory purposes, logistic regression was
performed with treatment, baseline MTX status, prior
anti-TNF use, disease duration category (<2 years vs.
≥2 years), and baseline response as covariates.
Correlations between PROs and clinical disease activity
measures of DAS28 using C-reactive protein (DAS28[CRP]),
log(CRP), tender joint count (TJC), and swollen joint
count (SJC) at week 12 were analyzed for all patients (ITT
population) using Pearson correlations. They were inter-
preted as <0.3 = low correlation, ≥0.3 to <0.5 =moderate
correlation, ≥0.5 to <0.7 = high correlation, and ≥0.7 to
1.0 = very high correlation [20]. Sensitivity analysis was
conducted using Spearman correlations.
The ability of RAPID3 and RADAI to detect changes
in patient-reported disease activity from baseline to week
12 in CZP patients was quantified as effect size (ES =
mean change/standard deviation [SD] of baseline score)
and relative efficiency (RE = ES2 of parameter x/ES2 of
reference parameter) [20], with DAS28[CRP] used as the
reference measure.
Number needed to treat (NNT) was assessed using
the following formula: NNT = 1/(response in active
treatment − response in placebo group) [20]. Missing data
for parameters on which NNT was calculated or MCID




A total of 1063 patients were randomized, of whom
212 were entered in the placebo arm and 851 in the
CZP arm. Of the 1063 randomized patients, 955
(89.8 %) completed the 12-week, double-blind phase:
184 (86.8 %) in the placebo group and 771 (90.6 %) in
the CZP group. All 955 patients were entered in the
open-label extension, and 809 (84.7 %) completed week
28. A similar percentage of patients in both the placebo
(n = 80, 37.7 %) and CZP groups (n = 320, 37.6 %) had
prior anti-TNF exposure at RCT baseline. Details of
the REALISTIC trial, including primary and secondary
outcomes, were previously reported [10]. At baseline,
the patients’ mean age was 55 years, 78 % were female,
and mean disease duration was 8.7 years. The patients
had active RA with, on average, high DAS28(CRP) and
high PRO scores at baseline (Table 1). The REALISTIC
study met its primary efficacy endpoint (a statistically
significant higher CZP ACR 20 % response rate at week
12 compared with placebo) [10].
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Impact of CZP on PROs of fatigue, sleep, pain, PtGA,
HAQ-DI, RADAI-TS, and RAPID3
As shown in Fig. 1, early and clinically meaningful im-
provements in PROs were observed. Improvements in
HAQ-DI, pain, and fatigue were reported with CZP
compared with placebo from week 2 (first time point
assessed) through week 12 (end of RCT) (Fig. 1a, c, d).
Sleep disturbance was significantly reduced in the CZP
group from week 6 onward (Fig. 1b). Improvements ob-
served from baseline to week 12 were maintained to
week 28 in the CZP-treated patients (Fig. 1). Clinically
important improvements in PtGA were also observed in
CZP-treated patients compared with placebo-treated pa-
tients from week 2 (PtGA least squares mean CFB −2.6 pla-
cebo vs. −14.9 CZP; p < 0.001) to week 12 (PtGA CFB −7.7
placebo vs. −20.4 CZP; p < 0.001). Improvements were
maintained up to week 28 in the CZP-treated patients
(PtGA CFB −24.3 at week 28).
At week 12, compared with placebo patients, more CZP
patients had improvements greater than or equal to the
MCID for fatigue (56.4 % vs. 46.2 %; p = 0.008), sleep prob-
lems (49.7 % vs. 42.5 %; p = 0.058), pain (59.0 % vs. 42.0 %;
p < 0.001), and PtGA (59.5 % vs. 42.5 %; p < 0.001). Differ-
ences between treatment arms for MCID improvement
were seen by week 2 for fatigue (p < 0.001), pain (p < 0.001),
and PtGA (p < 0.001). Rates of CZP patients reporting
MCID were maintained up to week 28 (fatigue 64.4 %,
sleep problems 56.2 %, pain 68.6 %, and PtGA 69.7 %
[observed case]).
Improvements in RADAI-TS and RAPID3 were ob-
served in the CZP group compared with placebo from
week 2 to week 12 (p < 0.001 CZP vs. placebo, all time
points) (Fig. 2a, b). More CZP patients than placebo pa-
tients achieved improvements greater than or equal to the
MCID in RADAI-TS and RAPID3 from week 2 to week
12 (p < 0.001 CZP vs. placebo, all time points) (Fig. 2c, d),
with improvements maintained up to week 28 in CZP pa-
tients (Fig. 2). The NNT to achieve an MCID in RADAI-
TS and RAPID3 at week 12 was approximately 4.5 and 5.6
patients, respectively. More CZP patients achieved
RAPID3 scores ≤6 from week 2 onward, with 34.5 % of
CZP patients and 13.7 % of placebo patients achieving
RAPID3 scores ≤6 at week 12 and 40.3 % of CZP patients
achieving RAPID3 scores ≤6 at week 28.
Correlation between PROs and clinical measures of RA
signs and symptoms
Correlations between PROs assessed at week 12 after
treatment were variable (Fig. 3). Correlations greater
than 0.7 were seen between patient-assessed pain and
RAPID3, PtGA, and RADAI-TS and also between
RAPID3 and both PtGA and RADAI-TS. Correlations
between 0.5 and 0.7 were found between RADAI-JS and
pain, PtGA, HAQ-DI, RAPID3, and RADAI-TS; between
RADAI-TS and fatigue, PtGA, and HAQ-DI; between
fatigue and pain, RAPID3, and PtGA; and between
HAQ-DI and RAPID3. Other correlations were less than
0.5 (Fig. 3).
Selected PROs were correlated with several clinical in-
dices (Fig. 3). DAS28(CRP) was correlated at 0.7 with
RAPID3 and greater than 0.5 with pain, PtGA, HAQ-DI,
RADAI-TS, and RADAI-JS. A correlation of 0.53 was
observed between RADAI-JS and TJC. Lower correla-
tions (i.e., less than 0.5) were observed between SJC/TJC
and PROs, and correlations were generally less than 0.3
between both CRP and hemoglobin levels and PROs
(Fig. 3).
Correlations were also assessed between various clin-
ical indices of RA signs and symptoms (Fig. 3). Within
this analysis, a strong correlation of 0.83 was seen be-
tween DAS28(CRP) and TJC, as well as correlations of
0.58 between SJC and TJC and 0.68 between SJC and
DAS28(CRP). Correlations less than 0.5 were observed
between CRP and SJC, TJC, and DAS28(CRP).
Sensitivity analyses using Spearman correlations yielded
results similar to those in the primary analysis.
Comparative responsiveness of RADAI-TS, RADAI-JS, and
RAPID3 in CZP-treated patients
Effect sizes of RADAI-TS, RADAI-JS and RAPID3 be-
tween baseline and Week 12 were satisfactory in the
Table 1 Baseline disease characteristics and PRO scores in the
ITT population
Placebo (n=212) CZPa (n=851)
Clinical characteristics
Disease duration, yr, median (min–max) 6.3 (0.3–49.0) 5.43 (0.2–52.0)
Tender joint count, mean (SD)b 14.7 (6.6) 14.7 (6.6)
Swollen joint count, mean (SD)b 11.1 (5.2) 11.8 (5.6)
DAS28(CRP), mean (SD) 5.7 (0.9) 5.7 (0.9)
DAS28(ESR), mean (SD) 6.4 (0.9) 6.4 (0.9)
Baseline patient-reported outcomes
Fatigue Assessment Scale score,
mean (SD) (0––10)
6.4 (2.2) 6.2 (2.2)
Medical Outcomes Study Sleep Problem
Index II score, mean (SD) (0–100)
48.1 (19.9) 47.6 (19.5)
Pain VAS score, mean (SD) (0–100) 62.3 (22.9) 58.8 (23.3)
PtGA VAS score, mean (SD) (0–100) 61.6 (20.7) 59.2 (22.1)
RADAI-TS, mean (SD) (0–10) 5.7 (1.9) 5.6 (1.8)
RAPID3, mean (SD) (0–30) 15.5 (5.4) 14.7 (5.5)
CRP C-reactive protein, CZP certolizumab pegol, DAS28 Disease Activity Score in
28 joints, ESR erythrocyte sedimentation rate, PRO patient-reported outcome, SD
standard deviation, VAS visual analog scale, FAS Fatigue Assessment Scale, PtGA
Patient Global Assessment of Disease Activity, ITT intention to treat, RADAI-TS
Rheumatoid Arthritis Disease Activity Index total score, RAPID3 Routine Assessment
of Patient Index Data 3
aCZP dose: 400 mg at weeks 0, 2, and 4 (loading dose), then 200 mg at weeks
6, 8, and 10
b28-joint assessment
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CZP-treated patients (Table 2). Effect sizes are reported as
negative since lower scores in these outcomes signify im-
provement in symptoms. Relative efficiency compared
with DAS28(CRP) was good only in patients with over 9
affected joints at baseline (Table 2; CZP-treated patients).
Discussion
We report rapid and consistent improvements in mul-
tiple PROs after CZP treatment in a group of patients
with active RA. The study included patients not usually
enrolled in RA clinical trials due to comorbidities, ex-
cluding only those with a history of chronic, serious, or
life-threatening infection; patients with any current in-
fection; patients with uncontrolled renal, hepatic, car-
diac, or neurological disease; and patients with either
concurrent or a history of malignancy. Additionally, pa-
tients with either early or late disease and a history of
previous DMARD use (including prior anti-TNF, used in
40 % of patients) were permitted to participate in the
study [10]. A range of correlations between PROs and
clinical indices of RA signs and symptoms were seen,
highlighting the importance of PROs for assessing the
full impact of RA on patients. Finally, the responsive-
ness, as measured by ES and RE, of RADAI and RAPID3
compared with other composite clinical indices of CZP
therapeutic efficacy suggests that these PROs can be
used to assess treatment outcomes in trial settings.
The treatment effects of CZP on the PROs assessed
demonstrated rapid onset, with clinically important im-
provements in pain, fatigue, and PtGA observed from
the first assessment (week 2). Beneficial effects were also
seen in the previously reported clinical observations of
CZP therapy in the REALISTIC trial [10]. Moreover,
these observations are consistent with findings from the
RAPID and FAST4WARD studies of CZP in patients
with RA, in which clinical benefits were seen as early as
week 1 [21–23].
The ability to evaluate the clinical significance of ob-
served improvement in parameters important to the pa-
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Fig. 1 Adjusted mean least squares (LS) change from baseline in a fatigue, b sleep disturbance, c pain, and d Health Assessment Questionnaire-
Disability Index (HAQ-DI) (intention-to-treat population, last observation carried forward; placebo n = 212, CZP n = 851). ap < 0.001 for CZP vs. pla-
cebo by analysis of covariance (ANCOVA); bp≤ 0.01 for CZP vs. placebo by ANCOVA. CZP certolizumab pegol; FAS Fatigue Assessment Scale, MOS-
SPI Sleep Problem Index II domain of the 12-item Medical Outcomes Study Sleep Scale, OLE open-label extension, VAS visual analogue scale
Pope et al. Arthritis Research & Therapy  (2015) 17:343 Page 5 of 10
trials. We investigated this by analyzing whether the pro-
portion of patients reporting MCIDs in PROs could dif-
ferentiate CZP from placebo, even in a short-term trial.
This approach has been validated previously using the
internal anchor-based analysis to derive MCIDs. For ex-
ample, PtGA and pain have been used to differentiate
abatacept and placebo in patients with RA in two major
RCTs [14, 24, 25]. Those studies demonstrated that
MCIDs for activity limitation, fatigue, and sleep prob-
lems can be used as benchmarks in clinical trials to as-
sess patient improvement. The results presented in the
present report broadly support this conclusion. Although
there was a placebo response for patients meeting MCID
for PROs, consistent with observations in other random-
ized trials assessing PROs [26], more patients receiving
active treatment achieved the MCID. Our results are
concordant with the magnitude of change in PROs
reported previously after CZP treatment in the RAPID
trials [23, 27], as well as for other anti-TNFs in random-
ized and controlled studies [28]. Improvements in PRO
MCID achievement after CZP therapy, compared with con-
trol patients participating in the RAPID 1 and RAPID 2 tri-
als, were also linked to improvements in social functioning,
as measured by participation in family, social, and leisure
activities and productivity at work and at home [29].
We observed marked and rapid improvements from
baseline in fatigue in patients who received CZP com-
pared with patients receiving placebo, and these im-
provements were maintained to week 28. Fatigue is now
recognized as an outcome of major importance, being
highly prevalent (present in up to 70 % of patients with
RA), as severe and frequent as pain, and consistently pri-
oritized by patients themselves as one of their top out-

















































2 6 12 20 28

































































































2 6 12 20 28
PBO (n=212)
CZP (n=851)
Fig. 2 Rheumatoid Arthritis Disease Activity Index total score (RADAI-TS) and Routine Assessment of Patient Index Data 3 (RAPID3) responses.
a Adjusted mean least squares (LS) change from baseline in RADAI-TS. b Adjusted mean LS change from baseline in RAPID3. c Percentage of
patients reporting improvements greater than or equal to the minimal clinically important difference (MCID) in RADAI. d Percentage of patients
reporting improvements greater than or equal to the MCID in RAPID3 (intention-to-treat population, placebo n = 212, CZP n = 851). ap < 0.001
CZP vs. placebo by analysis of covariance; bp < 0.001 CZP vs. placebo by logistic regression. CZP certolizumab pegol, OLE open-label extension,
PBO placebo
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recommended in clinical trials of RA treatments [31]. Fur-
thermore, fatigue is common across all rheumatic dis-
eases, correlates with all measures of distress, and predicts
dysfunction at work and overall health status [32].
Sleep disturbance is increased in patients with RA, and
a prior study of MOS sleep scales in 8676 patients with
RA suggested that sleep problems are linked to pain,
mood, and RA disease activity [33]. In the present study,
sleep improvement was associated with an improvement
in fatigue measures. CZP treatment was associated with
significant sleep improvement compared with the placebo
treatment. TNF-α has been implicated in regulating slow-
wave brain function and sleep propensity; consequently, it
is thought to play a role in normal sleep cycles as well as
the disturbed sleep associated with a number of disease
pathologies, including RA [34, 35]. However, improve-
ment in sleep could be due to improvement in RA signs
(inflammation) and symptoms (pain). Other studies have
also shown a beneficial effect of anti-TNFs on sleep in pa-
tients with RA; however, further research is required [36].
Using correlation analysis, we highlighted the value of
using PROs to evaluate treatment benefit in patients
Fig. 3 Correlations between clinical measures of rheumatoid arthritis (RA) signs and symptoms and patient-reported outcomes in overall RA
population (placebo and CZP combined, intention-to-treat population). CRP C-reactive protein, CZP certolizumab pegol, DAS28 Disease Activity
Score in 28 joints, ESR erythrocyte sedimentation rate, FAS Fatigue Assessment Scale, HAQ-DI Health Assessment Questionnaire-Disability Index,
JS joint score, MOS-SPI Sleep Problem Index II domain of the 12-item Medical Outcomes Study Sleep Scale, PtGA Patient Global Assessment of
Disease Activity, RADAI Rheumatoid Arthritis Disease Activity Index, RAPID3 Routine Assessment of Patient Index Data 3, TS total score
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with RA. Correlations between 0.3 and 0.7 were observed
between clinical indices of RA signs and symptoms and
the PROs PtGA, pain, and fatigue. We also found correla-
tions between 0.3 and 0.7 for all PROs measured and dis-
ability detected by the HAQ-DI. This demonstrated that
PROs measure aspects that are related to, but not the
same as, clinical outcomes. However, it should be noted
that sleep problems correlated poorly with pain and PtGA
and also with clinical indices of RA signs and symptoms
(e.g., DAS28[CRP], CRP, physician-reported TJC and SJC).
This is not surprising, as sleep problems are likely multi-
factorial, whereas pain may be more closely related to RA
disease activity, although it may still reflect damage and
other comorbidities.
The results reported herein suggest that PRO indices
may be useful clinical tools, complementary to other
measures, for assessing RA disease activity. We found
that correlations between DAS28(CRP) and RADAI or
RAPID3 were between 0.5 and 0.7 (Fig. 3) in the overall
RA population, and the effect sizes of these PROs were
clinically important. This suggests that these PROs in
particular may provide important additional information
concerning treatment efficacy. Comparable responsive-
ness of RADAI and RAPID3 and the clinical measure
DAS28(CRP) to CZP treatment was also demonstrated
in patients with very active disease, further supporting
this conclusion in these patients.
The NNT to achieve MCID in RADAI-TS and
RAPID3 were 4.5 and 5.6 patients, respectively. While
these values appear higher than those determined in the
CZP RAPID trial, where NNT was 2–3 [27], this may be
due to the broader patient population represented in the
REALISTIC trial, combined with a shorter trial duration.
The number of “real-world” patients with RA in this
study was large (N = 1063), especially those randomized
to CZP (n = 851), which is a strength of this study. A
possible limitation is the short-term length of the trial,
which allowed for detection of early rapid improvements
in PROs but excluded analysis of longer-term outcomes.
In particular, 12 weeks may have been an insufficient
period within which to adequately investigate the associ-
ation of sleep improvements with other outcomes.
HAQ-DI scores have been shown to be predictive of
long-term patient prognosis [37]. Currently, there is lim-
ited information available on the predictive value of
other PROs on long-term patient outcomes such as dis-
ability, mortality, and health resource use. Without this
validation, PROs remain indictors of disease symptom
severity rather than indicators of long-term patient prog-
nosis. We also noted high rates of improvement greater
than or equal to the MCID for PROs in patients ran-
domized to the placebo group. As patients maintained
their current treatment regimens, many patients in the
placebo group were concurrently receiving MTX. As im-
provements in PROs observed for this group tended to
plateau by week 12, the observed response may have
been a consequence of patient expectations of treatment
and/or regression to the mean, an effect extensively re-
ported elsewhere [38]. We were also unable to relate
PROs to radiographic changes, as radiographs were not
evaluated in the REALISTIC study. It should also be
noted that all reported p values and confidence intervals
are nominal and can be interpreted only in an explora-
tory manner.
Conclusions
This study highlights the rapid changes seen in a range
of PROs in a representative RA population following
CZP therapy. Improvement in PROs after CZP treat-
ment indicates that the benefits of therapy extend be-
yond the primary composite clinical efficacy endpoints
to outcomes that are more meaningful to patients, with
differentiation between active treatment and placebo.
RADAI and RAPID3 demonstrated very high correlation
with each other and comparative responsiveness to
change, which is not surprising as they assess many of
the same variables. Correlations between clinical indices
of RA signs and symptoms and PROs suggest that PROs
can be used in conjunction with clinical outcomes to
more comprehensively assess the benefits of treatment
on the outcomes that are most highly valued by patients.
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